Novo Nordisk’s Two-Stage Catalyst: Earnings Due August 5 as CagriSema FDA Verdict Hovers
Novo Nordisk is entering a defining stretch of the year, with two pivotal events that could reshape the…
Novo Nordisk’s Two-Pronged Catalyst: An Analyst Upgrade and a €69 Million Research Bet
Novo Nordisk closed the week with a 3.21% gain, pushing its shares to €38.90 on Friday. The rally…
Novo Nordisk’s Three-Way Catalyst: Formulary Reset, EU Pill Approval, and Pipeline Data
Novo Nordisk’s Wegovy retains preferred CVS status but will share with Lilly’s Zepbound from Oct 2026. European regulators…